Ocugen, Inc. (OCGN)
NASDAQ$0.5373
Market Cap
$156.9M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
350 of 924
Rank in Industry
204 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
OCGN Insider Trading Activity
OCGN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $31,943 | 2 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Castillo Kirsten | director | 1 | $22,848 | 0 | $0 | $22,848 |
| Fernandes Prabhavathi | director | 1 | $9,095 | 0 | $0 | $9,095 |
About Ocugen, Inc.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development …
Insider Activity of Ocugen, Inc.
Over the last 12 months, insiders at Ocugen, Inc. have bought $31,943 and sold $0 worth of Ocugen, Inc. stock.
On average, over the past 5 years, insiders at Ocugen, Inc. have bought $59,645 and sold $14.5M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Castillo Kirsten (director) — $22,848. Fernandes Prabhavathi (director) — $9,095.
The last purchase of 10,000 shares for transaction amount of $9,095 was made by Fernandes Prabhavathi (director) on 2024‑11‑26.
List of Insider Buy and Sell Transactions, Ocugen, Inc.
| 2024-11-26 | Fernandes Prabhavathi | director | 10,000 0.0034% | $0.91 | $9,095 | -18.56% | ||
| 2024-11-22 | Castillo Kirsten | director | 25,000 0.0086% | $0.91 | $22,848 | -18.32% | ||
| 2023-06-14 | Zhang Junge | director | 200,278 0.0886% | $0.50 | $99,999 | +10.13% | ||
| 2023-02-16 | Sale | Musunuri Shankar | Chief Executive Officer | 100,000 0.046% | $1.08 | $108,000 | -49.04% | |
| 2023-01-17 | Sale | Musunuri Shankar | Chief Executive Officer | 100,000 0.045% | $1.28 | $128,000 | -56.90% | |
| 2022-12-16 | Sale | Musunuri Shankar | Chief Executive Officer | 95,809 0.0407% | $1.43 | $137,007 | -62.55% | |
| 2022-10-14 | Sale | Musunuri Shankar | Chief Executive Officer | 100,000 0.0484% | $1.66 | $166,000 | -49.62% | |
| 2022-10-06 | Sale | Kumar Ramesh | director | 4,500 0.0021% | $1.83 | $8,235 | -54.33% | |
| 2022-08-11 | Sale | Castillo Kirsten | 42,000 0.0211% | $2.91 | $122,220 | -58.58% | ||
| 2022-07-18 | Sale | Kumar Ramesh | 7,500 0.0036% | $2.57 | $19,275 | -49.19% | ||
| 2022-07-14 | Sale | Musunuri Shankar | Chief Executive Officer | 150,000 0.0716% | $2.72 | $408,000 | -52.09% | |
| 2022-05-13 | Sale | Musunuri Shankar | Chief Executive Officer | 125,000 0.0529% | $1.92 | $240,000 | -23.33% | |
| 2022-04-18 | Sale | Kumar Ramesh | 7,500 0.0038% | $2.83 | $21,225 | -33.85% | ||
| 2022-03-16 | Sale | Musunuri Shankar | Chief Executive Officer | 81,823 0.0367% | $2.65 | $216,831 | -31.01% | |
| 2022-02-14 | Sale | Musunuri Shankar | Chief Executive Officer | 90,000 0.045% | $3.74 | $336,600 | -39.01% | |
| 2022-01-18 | Sale | Kumar Ramesh | director | 7,500 0.0037% | $4.07 | $30,525 | -41.25% | |
| 2021-12-16 | Sale | Musunuri Shankar | Chief Executive Officer | 115,000 0.0613% | $5.22 | $600,300 | -50.70% | |
| 2021-11-16 | Sale | Musunuri Shankar | Chief Executive Officer | 115,000 0.0583% | $8.04 | $924,600 | -67.77% | |
| 2021-11-03 | Sale | Zhang Junge | director | 150,300 0.1049% | $17.32 | $2.6M | -79.03% | |
| 2021-11-02 | Sale | Zhang Junge | director | 149,700 0.0772% | $15.75 | $2.36M | -82.93% |
Total: 94
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Castillo Kirsten | director | 75000 0.0257% | $40,297.50 | 2 | 3 | |
| Fernandes Prabhavathi | director | 10000 0.0034% | $5,373.00 | 1 | 1 | |
| Lewis Michael | 3610570 1.2364% | $1.94M | 2 | 1 | ||
| Wilmslow Estates Ltd | 10 percent owner | 3610570 1.2364% | $1.94M | 2 | 1 | |
| Musunuri Shankar | Chief Executive Officer | 2190073 0.75% | $1.18M | 2 | 16 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$2,924,567 | 72 | -4.87% | $157.74M | |
$64,487,106 | 32 | -22.92% | $140.02M | |
$35,190,048 | 32 | 37.32% | $150.49M | |
$79,019,806 | 27 | 7.24% | $165.26M | |
$40,617,659 | 23 | 2.15% | $139.33M |
OCGN Institutional Investors: Active Positions
| Increased Positions | 55 | +39.86% | 8M | +9.8% |
| Decreased Positions | 53 | -38.41% | 16M | -20.15% |
| New Positions | 27 | New | 3M | New |
| Sold Out Positions | 25 | Sold Out | 4M | Sold Out |
| Total Postitions | 140 | +1.45% | 71M | -10.35% |
OCGN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $13,007.00 | 6.86% | 19.95M | +1M | +7.17% | 2024-12-31 |
| Vanguard Group Inc | $10,836.00 | 5.71% | 16.62M | -329,926 | -1.95% | 2024-12-31 |
| Geode Capital Management, Llc | $4,296.00 | 2.26% | 6.59M | +309,853 | +4.93% | 2024-12-31 |
| State Street Corp | $3,825.00 | 2.02% | 5.87M | -10M | -62.93% | 2024-12-31 |
| Gmt Capital Corp | $1,601.00 | 0.84% | 2.45M | 0 | 0% | 2024-12-31 |
| Northern Trust Corp | $1,569.00 | 0.83% | 2.41M | +227,150 | +10.42% | 2024-12-31 |
| Renaissance Technologies Llc | $1,361.00 | 0.72% | 2.09M | +2M | New | 2024-12-31 |
| Gsa Capital Partners Llp | $747.00 | 0.39% | 1.15M | +941,423 | +460.78% | 2024-12-31 |
| Ubs Group Ag | $635.00 | 0.34% | 974,643 | +405,776 | +71.33% | 2024-12-31 |
| Morgan Stanley | $616.00 | 0.33% | 944,621 | -16,806 | -1.75% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.